A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
The latest deal over a CD47 asset has got investors wondering who could be next.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.